Introduction

Brain tumor is a collection or Cancer is a debilitating disease whose trend is continuously increasing. The most studied molecular deviations in cancer are genetic alteration. Metabolism of tumor cell is different to some extent as compared to normal cell. In order to defeat cancer, mechanism of disease must be well understood [1]. Tumor growth is associated with angiogenesis. For the proper growth of tumor new vessels supplying the tumor with oxygen and nutrients is necessary and it allows cancerous cell to invade adjacent tissue [2]. Intracellular hypoxia and transcription factors which responds to the change in oxygen concentration are created by fast growing tumors [3,4]. Brain tumor is a collection or mass of abnormal cells in brain (AboutTM). Brain tumor represent one of the largest public health problem [5]. The significant health burden represented by cancer has lead to the pursuit of a more comprehensive understanding of the changes driving tumor initiation, progression and metastasis. Broad categories of brain tumor have been studied like glioma, astrocytoma, glioblastoma, ependymoma, oligodendroglioma, and meningiothe. The WHO classification of brain tumor is based on histology and classified from grade 1 to 4 where grade 4 is most undifferentiated one. The more the undifferentiated the more poor prognosis and more fatal it is. Tumors which are confined within the skull cavity is mainly the brain tumor. They mainly originate from the supportive cell population in brain tissue, neuro-epithelial cells and meninges which protect the brain. Brain tumor can be benign or malignant and it originates in different anatomical location of brain and CNS. Gliomas constitute about 2% of all adult tumor it is fourth largest cause of cancer death due to its aggressive nature. This type of tumor is a broad category of brain and spinal cord tumor that arises from the supportive cells of the brain called neuroepithelial or glial cells. Based on their cellular origin and the degree of malignancy these gliomas are classified histologically and immune histochemically.

The degree of malignancy which is graded from 1-4 according to WHO (world health organization) grading system [6]. Astrocytoma are most abundant glial cell and these are most common gliomas tumor. Low grade of these types of tumor are uncommon. These are generally slow growing tumor. Anaplastic astrocytoma or astrocytoma 3 grows rapidly and invasively. Survival time varies from high to low grade tumor [7]. Glioblastoma also known as grade 4 astrocytomas constitute about 50% of all gliomas and are the most common intracranial malignancy [8]. Oligodendrogliomas are composed of cells that morphologically resemble oligodendroglia. These tumor of WHO grade 2 are slow growing and well differentiated tumors that show tendencies to diffusely infiltrate the surrounding brain. Anaplastic oligodendrogliomas WHO grade 3 show more malignant histological feature [6]. The cause of brain tumors is yet to be elucidated.

However some proposed mechanism for etiology is radiations and inheritance [9]. The symptoms mainly depends upon the size and localization of the tumor within the skull cavity. The most common symptoms are Headache, diplopia (double vision), raised ICP (intra cranial pressure), seizures, compression of vital centers, and personality disorders [10]. Genome encoded set of
proteomics comprises proteome. The proteome is dynamic and it alters in response to physiological status of the organism. The field which encompasses studying such sets is known as proteomics [11]. Proteomics has leveraged multiple sample preparation, fractionation and MS techniques over the past two decades to gain an understanding of tumor-specific changes in protein abundance and modification state. Fortuitously, biomarker studies also benefit from using tumor tissue in the discovery phase, as the tissue should have the highest concentration of any tumor-specific markers [5].

The source allows rapid screening, low sample consumption and accurate identification by proteomic technology. Almost all proteins normally present in cerebrospinal fluid (CSF) are derived from serum. The normal protein content of CSF is 100- to 400-fold lower compared to serum and depends upon the relative exclusion of macromolecules by the BBB (blood brain barrier) [12]. Under pathological conditions one may find that some of the proteins are usually not present in CSF. The presence of such proteins either results from disruption of the intrathecal production or BBB (blood brain barrier). An example of the latter is the increased CSF concentration of the tumor markers like LD5, beta-glucuronidase, and beta-2-microglobulin in cases of lepto-meningeal metastases [12,13].

The identification of proteins in the CSF that are intrathecally secreted or shed by the tumor or its microenvironment may reveal cellular mechanisms relevant to cancer biology. Also, it may result in the development of new tumor markers and may ultimately target new therapies. Recently, protein expression profiling has become a valuable tool in obtaining information about the state of protein circuits inside tumor cells and at the tumor host interface [14]. Proteomic techniques are applicable to serum but also to CSF for the detection of peptides and proteins resulting from diseases, including cancer. A major advantage of the search for disease-related proteins in CSF over serum is the lower protein concentration in the former.

Proteomics

Brain tumors have universally fatal outcomes; new therapeutics is desperately needed and will come from improved understandings of glioma biology. Exosomic are endosomally derived 30–100 nm membranous vesicles released from many cell types into the extracellular milieu; surprisingly, exosomes are virtually unstudied in neuron-oncology. These micro vesicles were used as vaccines in other tumor settings, but their immunological significance is unevaluated in brain tumors. Findings show that these vesicles have biophysical characteristics and proteomic profiles similar to exosomes from other cell types but that brain tumor exosomes have unique features (e.g., very basic isoelectric points, expressing the mutated tumor antigen EGFRvIII and the putatively immunosuppressive cytokine TGF-β). Administration of such exosomes into syngeneic animals produced both humoral and cellular immune responses in immunized hosts capable of rejecting subsequent tumor challenges but failed to prolong survival in established orthotopic models.

Control animals received saline or cell lysate vaccines and showed no antitumor responses. Exosomic and micro vesicles isolated from sera of patients with brain tumors also possess EGFR, EGFRvIII, and TGF-β. We conclude that exosomes released from brain tumor cells are biochemically/biophysically like other exosomes and have immune-modulating properties. They can escape the blood-brain barrier, with potential systemic and distal signaling and immune consequences. Biomarkers are measurable indicators of some biological state or conditions [15]. In this review article we describe some biomarkers which are used in brain tumor. Such as in case of leptomeningeal metastases we can use LD4, Beta-glucuronidase and Beta-2-microglobulin [12,16]. Urinary biomarkers also predict brain tumor presence and response to therapy. Recent studies confirmed and support the premise that tumor stage and progression correlate with urinary levels of MMPs [17]. Urinary levels of MMP-2 (gelatinase A) and MMP-9 (gelatinase B), and their complexes are elevated in patients with a variety of cancers, both organ confined and metastatic, both within and outside the urogenital tract.

These studies were the first to suggest that the measurement MMPs and related biomarkers in the urine of affected patients might represent a novel, noninvasive method of detecting disease status, progression, and therapeutic efficacy [17]. Given that [1], MMPs are present in brain tumors and [2] that urinary MMPs have shown utility as noninvasive biomarkers for non-central nervous system cancers, we initiated this study to determine whether urinary MMPs might have potential as noninvasive biomarkers to detect the presence of brain tumors. Glioblastoma tumor cells release micro vesicles (exosomes) containing mRNA, micro RNA and angiogenic proteins. These micro vesicles are taken up by normal host cells, such as brain microvascular endothelial cells. By incorporating an mRNA for a reporter protein into these micro vesicles, we demonstrate that messages delivered by micro vesicles are translated by recipient cells.

These micro vesicles are also enriched in angiogenic proteins and stimulate tubule formation by endothelial cells. Tumor-derived micro vesicles therefore serve as a means of delivering genetic information and proteins to recipient cells in the tumor environment. Glioblastoma microvesicles also stimulated proliferation of a human glioma cell line, indicating a self-promoting aspect. Messenger RNA mutant/variants and miRNAs characteristic of gliomas could be detected in serum microvesicles of glioblastoma patients. The tumour-specific (epidermal growth factor receptor) EGFRvIII was detected in serum microvesicles from 7 out of 25 glioblastoma patients. The tumour-specific (epidermal growth factor receptor) EGFRvIII was detected in serum microvesicles from 7 out of 25 glioblastoma patients. Thus, tumour-derived microvesicles may also provide diagnostic information and aid in therapeutic decisions for cancer patients through a blood test [18] (Table 1).

Techniques

Two-dimensional polyacrylamide gel electrophoresis (2D PAGE)

It is a widely used to study protein expression profiles with a high resolution for the separation of complex protein mixtures [12]. The identification of proteins separated by 2D PAGE has improved over the last decade due to advances in matrix-assisted laser desorption/ionization time-of-flight-mass spectrometry.
Theranostics of Brain, Spine & Neural Disorders

Matrix Assisted Laser Desorption/Ionisation is a soft ionization technique used in spectrometry allowing to analysis the biomolecules like DNA, protein, peptides. Biomolecules and synthetic polymers have low volatility and are thermally unstable, which has limited the use of MS as a means of characterization. These problems have been minimized through the development of MALDI-TOF MS, which allows for the mass determination of biomolecules by ionization and vaporization without degradation, a Laser beam used to ionize the sample. Protein sample have been characterized by HPLC or SDS PAGE by generating peptide maps. These peptide maps have been used as fingerprints of protein or as a tool to know the purity of a known protein in a known sample. Mass spectrometry gives a peptide map when proteins are digested with proteolytic enzymes like trypsin. This peptide map can be used to search a sequence database to find a good match from the existing database [22].

**Conclusion**

The growth in proteomics over the past decade has been driven by the pursuit of proteome-based information from the vast FFPE archives which exist around the world. This is largely a result of the possibility for combining proteomics with mining of the patient meta-data associated with the archived samples, which can include disease course and patient outcome. These kinds of studies would be hugely beneficial to the field, as it would no longer be difficult to assemble large retrospective cohorts. Quantitative proteomics still requires standardization to overcome variability in protein extraction and fractionation results. Quantitative proteomic studies have shown a greater level of success, most likely due to the combination with other modern techniques. It is this success which has led to other quantitative studies. As discussed in this review, researchers identified potential prognostic tumour markers using quantitative proteomics. As evidenced by this review, about proteomics and other diagnostic techniques for brain tumor archives are an incredibly valuable resource and will invariably form a significant component of large-scale retrospective studies in future [23-45] (Table 1).

**Table 1:** CSF: cerebrospinal fluid; PCNSL: primary central nervous system lymphoma; bHCG: Human chorionic gonadotropin; AT III: antithrombin III; CXCL 13: chemokine C-X-C motif ligand; IL 10: Interleukin 10; VEGF: vascular endothelial growth factor; PGD2: Prostaglandin-D2 synthase; CYFRA 21-1: cytokeratin-19 fragment; NSE: neuron-specific enolase; CEA: carcinoembryonic antigen; MIC-1: macrophage inhibitory cytokine-1; GDF15: growth differentiation factor 15.

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>Brain tumor</th>
<th>Mutated gene</th>
<th>Method of Detection</th>
</tr>
</thead>
<tbody>
<tr>
<td>LD4</td>
<td>Leptomeningeal metastases</td>
<td>Mutation in EGFR gene</td>
<td>CSF proteomics analysis [23]</td>
</tr>
<tr>
<td>Beta-glucuronidase</td>
<td>Cancer cells</td>
<td>Medulloblastoma, primitive neuroectodermal tumors, germ cell tumor, ependymoma and glioma</td>
<td>CSF cytology [24,25]</td>
</tr>
<tr>
<td>Beta-2-microglobulin</td>
<td>bHCG and AFP</td>
<td>Intracranial malignant germ cell tumors, Pediatric brain tumors</td>
<td>Mutation in b-HCG and AFP genes</td>
</tr>
<tr>
<td>CD27 AT III, chemo attractant, CXCL13, CXCL12 and IL10</td>
<td>Immunoglobulin G Ig</td>
<td>Cerebral low grade lymphoma</td>
<td>Mutation in Immunoglobulin G Ig genes</td>
</tr>
<tr>
<td>EGFR</td>
<td>Brain metastases from lung adenocarcinoma</td>
<td>Mutation in EGFR gene</td>
<td>CSF proteomics analysis [31]</td>
</tr>
<tr>
<td>VEGF and stromal cell derived factor (SDF)-1</td>
<td>Brain metastasis from lung and breast cancer</td>
<td>Mutation in VEGF and stromal cell derived factor (SDF)-1 genes</td>
<td>CSF proteomics analysis [32]</td>
</tr>
<tr>
<td>PGD2</td>
<td>Medulloblastoma</td>
<td>Mutation in PGD2 gene</td>
<td>CSF proteomics analysis [33]</td>
</tr>
<tr>
<td>CYFRA 21-1, NSE and CEA</td>
<td>Meningeal carcinoma</td>
<td>Mutation in CYFRA 21-1, NSE and CEA genes</td>
<td>CSF proteomics analysis [34]</td>
</tr>
<tr>
<td>MIC-1 GDF 15</td>
<td>Glioblastoma</td>
<td>Mutation in MIC-1 GDF 15 genes</td>
<td>CSF proteomics analysis [35]</td>
</tr>
<tr>
<td>miR-19, miR-21 and miR-92a</td>
<td>PCNSL</td>
<td>Mutation in miR-19, miR-21 and miR-92a genes</td>
<td>CSF microRNA analysis [36]</td>
</tr>
<tr>
<td>--------------------------</td>
<td>-------</td>
<td>---------------------------------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>miR-10b and miR-21</td>
<td>Glioblastoma and brain metastasis</td>
<td>Mutation in miR-10 and miR-21 genes</td>
<td>CSF microRNA analysis [37]</td>
</tr>
<tr>
<td>Membrane of miR-200 family</td>
<td>Brain metastasis from lung and breast cancers</td>
<td>Mutation in miR-200 genes</td>
<td>CSF microRNA analysis [38]</td>
</tr>
<tr>
<td>miR-93, miR-45, miR-71, miR-223 and miR-125b</td>
<td>Glioblastoma, medulloblastoma, brain metastasis and lymphoma</td>
<td>Mutation in miR-93, miR-71, miR-223 and miR-125b genes</td>
<td>CSF micro RNA analysis [39]</td>
</tr>
</tbody>
</table>

Reference


